The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of ...
SERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a ...
Clinical Trials Arena on MSN
AstraZeneca’s cancer pipeline posts two wins and a loss
The UK-Swedish pharma giant has shared readouts from key portfolio assets such as Enhertu, Tagrisso and Etcamah.
AstraZeneca's breast-cancer pill, Etcamah, failed to significantly slow disease progression in a late-stage trial when ...
AstraZeneca AZN announced that a phase III study evaluating a combination therapy involving its recently approved breast ...
The ink was barely dry on the FDA approval letter for AstraZeneca’s Etcamah before the oral SERD suffered a key clinical ...
AstraZeneca’s breast cancer pill camizestrant (Etcamah) failed to improve progression-free survival in a late-stage trial ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...
Oncology sales comprise around 27% of its total revenues. In the second quarter of 2026, oncology revenues increased 3% to $4.17 billion, with 2% operational growth, driven by drugs like Padcev, ...
Pfizer PFE and AstraZeneca AZN are global pharmaceutical leaders with a strong presence in oncology. For Pfizer, oncology is a major growth driver, contributing about 27% of total revenues. Beyond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results